Differences in immunoreactive trypsin values between type of feeding and ethnicity in neonatal cystic fibrosis screening: a cross-sectional study

Orphanet Journal of Rare Diseases

Vicente Francisco Gil-Guillén³  Herminia Manero⁴  María Mercedes Rizo-Baeza¹  Antonio Palazón-Bru³  Ana María Roldán⁴  Ernesto Cortés² 

[1] Nursing Department, University of Alicante, San Vicente del Raspeig, Spain;Pharmacology, Paediatrics and Organic Chemistry Department, Miguel Hernández University, San Juan de Alicante, Spain;Clinical Medicine Department, Miguel Hernández University, Carretera de Valencia-Alicante S/N, San Juan de Alicante, 03550, Spain;Clinical Analysis Department, Alicante General University Hospital, Alicante, Spain

关键词: Ethnic groups;    Nutrition;    Neonatal screening;    Cystic fibrosis;   

Others  :  1149454
DOI  :  10.1186/s13023-014-0166-9

 received in 2014-06-20, accepted in 2014-10-16,  发布年份 2014

【 摘 要 】

Background

We studied the differences in immunoreactive trypsin (IRT) in neonatal screening for cystic fibrosis (CF) associated individually with the age of the newborn, ethnicity and environmental temperature. In this study, we determine the overall influence of environmental temperature at birth, gender, feeding, gestational age, maternal age and ethnic origin on an abnormal IRT result.

Methods

Cross-sectional observational study. A sample was selected of newborns from Alicante (Spain) who underwent neonatal CF screening in 2012¿2013. Primary variable: abnormal IRT levels (?65 ng/ml). Secondary variables: gender, maternal origin, maternal age (years) (<20, 20¿40, >40), gestational age (weeks) (<32, 32¿37, >37), type of feeding (natural, formula, mixed and special nutrition), >20 days from birth to blood collection, and average temperature during the month of birth (in°C). Using a multivariate logistic regression model the adjusted odds ratios (ORs) were estimated to analyze the association between atypical IRT levels and the study variables. The ? error was 5% and confidence intervals (CI) were calculated for the most relevant parameters.

Results

Of a total of 13,310 samples, 199 were abnormal (1.34%). Significant associated factors: feeding method (natural???OR?=?1; mixed???OR?=?0.53, 95% CI: 0.31-0.89; formula???OR?=?0.72, 95% CI: 0.48-1.07; special???OR?=?21.88, 95% CI: 6.92-69.14; p?

Conclusions

Newborns receiving special nutrition have a 20-fold higher risk for abnormal IRT levels, and screening is advisable once normalized feeding is initiated. It is advisable to consider ethnic variability. Seasonality was not important.

【 授权许可】

   
2014 Cortés et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1][http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5313a1.htm] webcite Centers for Disease Control and Prevention (CDC): Morbidity and mortality weekly report. 2004, .
• [2]Southern KW, Mérelle MM, Dankert-Roelse JE, Nagelkerke AD: Newborn screening for cystic fibrosis.Cochrane Database Syst Rev 2009, 1:CD001402.
• [3]Farrell PM, Kosorok MR, Rock MJ, Laxova A, Zeng L, Lai HC, Hoffman G, Laessig RH, Splaingard ML: Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics 2001, 107:1-13.
• [4]McKay KO, Waters DL, Gaskin KJ: The influence of newborn screening for cystic fibrosis on pulmonary outcomes in New South Wales. J Pediatr 2005, 147(3 Suppl):S47-S50.
• [5]Accurso FJ, Sontag MK, Wagener JS: Complications associated with symptomatic diagnosis in infants with cystic fibrosis. J Pediatr 2005, 147(3 Suppl):S37-S41.
• [6]Dankert-Roelse JE, Mérelle ME: Review of outcomes of neonatal screening for cystic fibrosis versus non-screening in Europe. J Pediatr 2005, 147(3Suppl):S15-S20.
• [7]Dodge JA, Lewis PA, Stanton M, Wilsher J: Cystic fibrosis mortality and survival in the UK: 1947¿2003. Eur Respir J 2007, 29:522-526.
• [8]Castellani C: Evidence for newborn screening for cystic fibrosis. Paediatr Respir Rev 2003, 4:278-284.
• [9]Castellani C, Macek M Jr, Cassiman JJ, Duff A, Massie J, ten Kate LP, Barton D, Cutting G, Dallapiccola B, Dequeker E, Girodon E, Grody W, Highsmith EW, Kääriäinen H, Kruip S, Morris M, Pignatti PF, Pypops U, Schwarz M, Soller M, Stuhrman M, Cuppens H: Benchmark for cystic fibrosis carrier screening: a European consensus document. J Cyst Fibros 2010, 9:165-178.
• [10]Castellani C, Southern KW, Brownlee K, Dankert Roelse J, Duff A, Farrell M, Mehta A, Munck A, Pollitt R, Sermet-Gaudelus I, Wilcken B, Ballmann M, Corbetta C, de Monestrol I, Farrell P, Feilcke M, Férec C, Gartner S, Gaskin K, Hammermann J, Kashirskaya N, Loeber G, Macek M Jr, Mehta G, Reiman A, Rizzotti P, Sammon A, Sands D, Smyth A, Sommerburg O, et al.: European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros 2009, 8:153-173.
• [11]Gartner S, Casals T, Marin JL, Seculi JL, Asensio O, Hernandez JL, Prats R, Cobos N: Neonatal screening for cystic fibrosis in Cataluña.Spain Pediatr Pulmonol 2003, 25(Suppl):221.
• [12]Farriaux JP, Vidailhet M, Briard ML, Belot V, Dhondt JL: Neonatal screening for cystic fibrosis: France rises to the challenge. J Inherit Metab Dis 2003, 26:729-744.
• [13]Cheillan D, Vercherat M, Chevalier-Porst F, Charcosset M, Rolland MO, Dorche C: False-positive results in neonatal screening for cystic fibrosis based on a three-stage protocol (IRT/DNA/IRT): should we adjust IRT cut-off to ethnic origin? J Inher Metabol Dis 2005, 28:813-818.
• [14]Ravine D, Francis RI, Banks DM: Non-specific elevation of immunoreactive trypsinogen in sick infants. Eur J Pediatr 1993, 152:348-349.
• [15]Therrell BL Jr, Hannon WH, Hoffman G, Ojodu J, Farrell PM: Immunoreactive trypsinogen (IRT) as a biomarker for cystic fibrosis: challenges in newborn dried blood spot screening. Mol Genet Metab 2012, 106:1-6.
• [16]Espada M, Dulín E: Procedimiento para la obtención de especímenes de sangre sobre papel de filtro en los Programas de Detección Precoz Neonatal de Errores Congénitos del Metabolismo. Quim Clin 2001, 20:81-88.
• [17][http://www.aecne.es] webcite Asociación Española de Cribado Neonatal (AECNE)..
• [18][http://publicaciones.san.gva.es/publicaciones/documentos/V.4285-2011.pdf] webcite Conselleria de Sanitat, Generalitat Valenciana: Programa de Cribado Neonatal de Enfermedades Congénitas en la Comunidad Valenciana..
• [19][http://www.aeped.es/sites/default/files/documentos/8_1.pdf] webcite Rellan S, García de Ribera C, Aragón MO: El recién nacido prematuro. Protocolos Diagnóstico Terapeúticos de la AEP: Neonatología. 2008. [].
• [20][http://www.eltiempo.es/aemet.html] webcite Agencia Española de Meteorología (AEMET)..
• [21]Priest FJ, Nevin NC: False positive results with immunoreactive trypsinogen screening for cystic fibrosis owing to trisomy 13. J Med Genet 1991, 28:575-576.
• [22]Rock MJ, Mischler EH, Farrell PM, Bruns WT, Hassemer DJ, Laessig RH: Immunoreactive trypsinogen screening for cystic fibrosis: characterization of infants with a false positive screening test. Pediatr Pulmonol 1989, 6:42-48.
• [23]Lewis PA: The Epidemiology of Cystic Fibrosis. In Cystic Fibrosis. 2nd edition. Edited by Hodson ME, Geddes DM. Arnold, London; 2000:13-25.
• [24]Bush A: Cystic fibrosis. In European lung white book. European Respiratory Society Journals Limited, Brussels; 2003:89-95.
• [25]Gregg RG, Simantel A, Farrell PM, Koscik R, Kosorok MR, Laxova A, Laessig R, Hoffman G, Hassemer D, Mischler EH, Splaingard M: Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods. Pediatrics 1997, 99:819-824.